The survival of developing motor neurons depends on factors secreted from skeletal muscles and from cells within the central nervous system. Although several members of the nerve growth factor protein family [neurotrophins (NTs)] are able to maintain developing rat motor neurons in vitro, only the brain-derived neurotrophic factor has been shown to have signicant effects on the survival of motor neurons in vivo. In the present study, we demonstrate that NT-4/5 also prevents ifijury-induced death of facial motor neurons in neonatal rats. Furthermore, facial motor neurons express a functional receptor for NT-4/5, whereas mRNAencoding NT-4/5 can be detected in their environment throughout embryonic and postnatal life. Thus, both NT-4/5 and brain-derived neurotrophic factor may be physiological survival factors for facial motor neurons and may serve as therapeutic agents for motor neuron disease. culture (9). Surprisingly, although NT-3 and brain-derived neurotrophic factor (BDNF) are both potent trophic factors for motor neurons in culture (9), only BDNF has significant effects on the survival of chicken and rat motor neurons in vivo (10-13). Furthermore, even the high-affinity receptor for a given NT is not always sufficient to elicit a physiological response (14) . Consequently, the physiological importance of putative motor neuron trophic factors must be experimentally determined in vivo. The present investigation is designed to examine the physiological role of NT-4/5 on motor neurons. Several complementary approaches are taken, including the demonstration of a pharmacological effect of NT-4/5 on degenerating motor neurons, the localization of functional NT-4/5 receptors on neonatal and adult motor neurons, and the demonstration of the expression of NT-4/5 in the muscle targets of motor neurons at different developmental stages. NT-4/5 is compared to BDNF in all the above measures of physiological significance.
NT-4/5 also prevents ifijury-induced death of facial motor neurons in neonatal rats. Furthermore, facial motor neurons express a functional receptor for NT-4/5, whereas mRNAencoding NT-4/5 can be detected in their environment throughout embryonic and postnatal life. Thus, both NT-4/5 and brain-derived neurotrophic factor may be physiological survival factors for facial motor neurons and may serve as therapeutic agents for motor neuron disease.
The survival of developing motor neurons depends on factors secreted by their muscle targets and by cells in the central nervous system (1) (2) (3) (4) (5) (6) , but the identity ofthese factors has not yet been fully established. The neurotrophins [NTs, members of the nerve growth factor (NGF) protein family] have been considered to have no direct effects on motor neurons in vitro (7, 8) . However, a recent study has demonstrated that all known NTs, except NGF, can promote the survival of embryonic rat motor neurons in culture (9) . Surprisingly, although NT-3 and brain-derived neurotrophic factor (BDNF) are both potent trophic factors for motor neurons in culture (9) , only BDNF has significant effects on the survival of chicken and rat motor neurons in vivo (10) (11) (12) (13) . Furthermore, even the high-affinity receptor for a given NT is not always sufficient to elicit a physiological response (14) . Consequently, the physiological importance of putative motor neuron trophic factors must be experimentally determined in vivo. The present investigation is designed to examine the physiological role of NT-4/5 on motor neurons. Several complementary approaches are taken, including the demonstration of a pharmacological effect of NT-4/5 on degenerating motor neurons, the localization of functional NT-4/5 receptors on neonatal and adult motor neurons, and the demonstration of the expression of NT-4/5 in the muscle targets of motor neurons at different developmental stages. NT-4/5 is compared to BDNF in all the above measures of physiological significance.
MATERIALS AND METHODS
Histolgy and Neuronal Counts in Animals with Facial Nerve Axotomies and NT Treatment. Postnatal day 0 (P0) SpragueDawley rats were anesthetized by hypothermia and subjected to a unilateral transection of the facial nerve, as described (13) .
NT-4/5, BDNF, a 1:1 mixture ofNT-4/5 and BDNF, or vehicle solution [acetic acid-acidified phosphate-buffered saline (pH 6.0)] (five animals per group) was applied to the proximal nerve stump in apiece ofgelfoam (Upjohn) as described (13) . Six days after surgery, animals were sacrificed by decapitation, and blocks that contain the pons/medulla were fixed by immersion in chilled Carnoy's solution overnight (4Q(). Blocks were subsequently dehydrated in alcohols and embedded in paraffin.
Serial coronal sections (7 pm) were stained with cresyl violet.
Three sections per case (one through the middle of the facial nucleus and two corresponding to planes at equal anterior and posterior distances from the middle level on each side of the brain) were taken for neuronal counts (six animals per group were counted from vehicle-, NT-4/5-, BDNF-, and NT-4/5-plus-BDNF-treated groups). Motor neurons were identified as Nissl-containing basophilic profiles with nucleoli and were counted at a x40 magnification by using a computerized image analysis system (software provided by Mark Molliver and adapted by Catherine Fleischman, The Johns Hopkins University School of Medicine).
*Bf in Situ Hybridization (ISH). A probe specific for fulllength trkB was generated by polymerase chain reaction (PCR) amplification of a 1.09-kb sequence whose 5' end corresponds to nucleotide 2249 of the tyrosine kinase (tk) region of rat trkB and whose 3' end corresponds to nucleotide 3339 of the 3' untranslated region. Amplification was performed using oligonucleotides 5'-GATAGAATGCATCACCCAGG-3' (sense) and 5'-TGTGATCGGAAACTGTGTCC-3' (antisense) as primers and the plasmid that contains the entire full-length rat trkB sequence as a template. The amplified product was cloned directly into the pCRII transcription vector (Invitrogen) by using a TA cloning kit (Invitrogen). This vector was then used to generate sense and antisense RNA probes for ISH in neonatal (P3) and adult (3 month old) rats as described (13) .
Retrograde Transport of lodinated NT-4/5. NT-4/5 was labeled by lactoperoxidase treatment using a modified Enzymobead (Bio-Rad) radioiodination procedure (15) . Recovery and radioactivity were determined by trichloroacetic acid precipitation of the labeled protein before and after gel filtration. The specific radioactivity of 1251-labeled NT-4/5 was 100 uCi/pg (1 Ci = 37 GBq). Radiolabeled NT-4/5 was tested for bioactivity in a quantitative rat trigeminal ganglion bioassay. The biological activity of 125I-labeled NT-4/5 determined by parallel dose-response curves was equivalent to that of the unlabeled factor. The iodinated factor was further characterized prior to its in vivo utilization on receptor binding assays using TrkB-IgG chimeric receptors. 1251-labeled NT-4/5 binding to these receptors was entirely com-Proc. Natl. Acad. Sci. USA 91 (1994) 3305 peted by an excess of unlabeled NT-4/5 but not NGF.
2"5I-labeled NT-4/5 was injected under the whisker pad of P3 rats (10 XCi per injection site; n = 5 rats) with and without a hundredfold excess of unlabeled NT-4/5 or NGF. Blocks containing the pontomedullary region were fixed 14 h later in phosphate-buffered 4% (wt/vol) formaldehyde for 2-3 days, embedded in paraffin, cut in the transverse plane (15 Mm), and processed for emulsion autoradiography (13) .
Northern Blot Analysis of trkD Expression in Neonatal and Adult Facial Motor Neurons. A probe corresponding to nucleotides 2249-3339 of the rat trkB (see above) or the entire trkB sequence was gel-purified and labeled with random hexanucleotides to a specific activity of 1 x 109 cpm/pg. Poly(A)+ RNA (10 pg) from pooled facial nuclei of PO and 3-month-old rats was prepared and analyzed using the above trkB probes as described (13) . trkB-hybridized filters were subsequently stripped and rehybridized with a mouse 'y-actin probe (labeled as above), which served as a loading control; actin-hybridized filters were exposed for 2 h at room temperature without intensifying screens.
PCR Analysis ofiB Expression in Axotomized Adult Facial
Motor Neurons. BDNF expression was studied in parallel to that of NT-4/5 to compare directly the levels of expression of NT-4/5 to those of an established motor neuron trophic factor. Three-month-old Sprague-Dawley rats were anesthetized with enflurane/nitrous oxide/oxygen and subjected to a unilateral transection ofthe facial nerve 2-3 mm distal to the stylomastoid foramen. Five days later, animals were sacrificed. Facial nuclei from lesioned (n = 3) and control (n = 3) rats were microdissected with a needle puncher from 300-Am-thick fresh frozen sections through the pontomedullary junction. Tissues were subjected to PCR analysis with primers specific for tk-containing rat trkB transcripts (sense, aa 395-403; antisense, aa 626-635) (9) . PCR Facial muscles from animals prepared as above were quickly dissected on ice and frozen [ages examined were embryonic day (E) 10, E15, E20, P2, and adult]. Facial nuclei were micropunched as above (ages examined were P0 and adult). PCR was performed using 10 pmol of rat BDNF-specific sense (aa 12-20) and antisense (aa 59-76) primers or using 10 pmol of rat NT-4/5-specific sense (aa 131-138) and antisense (aa 206-213) primers (9) .
RESULTS
To assess the physiological role and the therapeutic usefulness of NT-4/5, we investigated its ability to prevent the death of neonatal rat facial motor neurons after axotomy. The facial nerves of newborn rats were cut unilaterally, and 20 pg of NT-4/5 or vehicle was applied to the proximal nerve stump in a piece of gelfoam. Six days later, animals were sacrificed, and facial motor neurons ipsi-and contralateral to the lesion were counted. In vehicle-treated animals, there was, on average, a 72% loss of facial motor neurons on the lesioned side; gliosis (Fig. 3 A and B) . To (Fig. 4) blot analysis reveals three tk-containing mRNA species of 9.0, 4.8, and 1.6 kb. Because the full-length receptor requires 2.4 kb of coding sequence, the two larger species may code for the full-length receptor, whereas the 1.6-kb species may encode a soluble or membrane-associated tk-containing species (17) . The 7.5-, 2.4-, and 1.8-kb species detected by full-length trkB probes correspond to tk(-) TrkB species as characterized (17) . The fact that the 7.5-kb trkB mRNA species encoding a truncated TrkB receptor (17, 18 ) is up-regulated in the adult (Fig. 4D (Fig. 4E) . If NT-4/5 is to act as a physiological factor that supports the survival of facial motor neurons, then it should be present in the environment of these neurons, at least during the period of developmental cell death. Therefore, we ascertained the presence of NT-4/5 in innervation targets of facial motor neurons (facial musculature) and in the facial nucleus. RNA samples from the facial musculature of embryonic (E10, E1S, and E20), neonatal (P2), and adult (3 month old) rats and the facial nucleus of neonatal and adult rats were reverse-transcribed and then amplified in a PCR using NT-4/5-specific primers. NT-4/5 mRNA was present in facial muscles of embryonic and neonatal rats (Fig. 5A) , in the facial muscles of adult rats (Fig. 5B) , and in the facial nucleus of neonatal, but not adult, rats (Fig. SC) . BDNF mRNA was also expressed in the facial muscle at all ages examined (Fig. 5 A and B) and in the facial nucleus of neonatal and adult animals (Fig. SC) . Levels of BDNF mRNA in facial muscle appear to increase, whereas those of NT-4/5 appear to decrease after denervation (Fig. SB) . BDNF continues to be expressed in the axotomized facial nucleus in the adult (Fig. 5C) . DISCUSSION The ability of NT-4/5 to prevent the death of facial motor neurons after axotomy, the expression ofa functional NT-4/5 receptor by facial motor neurons, and the presence ofNT-4/5 in the facial musculature during embryonic development, including the period of physiological motor neuron death, indicate that NT-4/5, similar to BDNF, may be a physiological factor for the survival of facial motor neurons. The effects ofNT-4/5 on facial motor neurons and the reported in vivo effects of BDNF on these cells (10) (11) (12) (13) suggest that a subset of NTs transduced via TrkB are trophic factors for motor neurons.
In the present investigation of the role of NT-4/5 for a-motor neurons, we focused on motor innervation of the face. It is likely that the effects of BDNF (10) (11) (12) (13) and NT-4/5 on spinal motor neurons are identical. In addition, the presence of tk(+) TrkB isoforms in adult facial motor neurons and the persistence of these receptors after injury suggest that this NT may also act as a trophic factor for mature neurons. However, the direct investigation of the effects of NT-4/5 on adult motor neurons must await the availability of reliable lesion models (19) . The effects of NT-4/5 on degenerating motor neurons raise the possibility of the future use of this NT as a therapeutic agent for human motor neuron disease.
